125 related articles for article (PubMed ID: 10923648)
21. Synthesis and binding characteristics of [3H] H-Tyr-Ticpsi[CH2-NH] Cha-Phe-OH, a highly specific and stable delta-opioid antagonist.
Szatmári I; Tóth G; Kertész I; Schiller PW; Borsodi A
Peptides; 1999; 20(9):1079-83. PubMed ID: 10499425
[TBL] [Abstract][Full Text] [Related]
22. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
[TBL] [Abstract][Full Text] [Related]
23. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
24. Selective delta-opioid receptor antagonist N,N(CH3)2-Dmt-Tic-OH does not reduce ethanol intake in alcohol-preferring AA rats.
Ingman K; Salvadori S; Lazarus L; Korpi ER; Honkanen A
Addict Biol; 2003 Jun; 8(2):173-9. PubMed ID: 12850776
[TBL] [Abstract][Full Text] [Related]
25. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
[TBL] [Abstract][Full Text] [Related]
27. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).
Ondachi PW; Kormos CM; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
J Med Chem; 2018 Sep; 61(17):7525-7545. PubMed ID: 30117738
[TBL] [Abstract][Full Text] [Related]
28. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging.
Ryu EK; Wu Z; Chen K; Lazarus LH; Marczak ED; Sasaki Y; Ambo A; Salvadori S; Ren C; Zhao H; Balboni G; Chen X
J Med Chem; 2008 Mar; 51(6):1817-23. PubMed ID: 18311909
[TBL] [Abstract][Full Text] [Related]
30. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Balboni G; Onnis V; Congiu C; Zotti M; Sasaki Y; Ambo A; Bryant SD; Jinsmaa Y; Lazarus LH; Trapella C; Salvadori S
J Med Chem; 2006 Sep; 49(18):5610-7. PubMed ID: 16942034
[TBL] [Abstract][Full Text] [Related]
31. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
32. Rational design of dynorphin A analogues with delta-receptor selectivity and antagonism for delta- and kappa-receptors.
Guerrini R; Capasso A; Marastoni M; Bryant SD; Cooper PS; Lazarus LH; Temussi PA; Salvadori S
Bioorg Med Chem; 1998 Jan; 6(1):57-62. PubMed ID: 9502105
[TBL] [Abstract][Full Text] [Related]
33. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent delta-opioid antagonist.
Lovekamp T; Cooper PS; Hardison J; Bryant SD; Guerrini R; Balboni G; Salvadori S; Lazarus LH
Brain Res; 2001 May; 902(1):131-4. PubMed ID: 11376603
[TBL] [Abstract][Full Text] [Related]
35. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei.
Balboni G; Salvadori S; Guerrini R; Bianchi C; Santagada V; Calliendo G; Bryant SD; Lazarus LH
Peptides; 2000 Nov; 21(11):1663-71. PubMed ID: 11090920
[TBL] [Abstract][Full Text] [Related]
36. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
37. Novel C-terminus modifications of the Dmt-Tic motif: a new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors.
Pagé D; Naismith A; Schmidt R; Coupal M; Labarre M; Gosselin M; Bellemare D; Payza K; Brown W
J Med Chem; 2001 Jul; 44(15):2387-90. PubMed ID: 11448220
[TBL] [Abstract][Full Text] [Related]
38. Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist.
Spetea M; Tóth F; Schütz J; Otvös F; Tóth G; Benyhe S; Borsodi A; Schmidhammer H
Eur J Neurosci; 2003 Jul; 18(2):290-5. PubMed ID: 12887410
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive study on the putative δ-opioid receptor (sub)types using the highly selective δ-antagonist, Tyr-Tic-(2S,3R)-β-MePhe-Phe-OH.
Birkas E; Bakota L; Gulya K; Wen T; Pintar J; Tóth G; Szucs M
Neurochem Int; 2011 Aug; 59(2):192-201. PubMed ID: 21672586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
